Phone: (011) 7541-421, 3409-301, 3409-335, 6547-293, 3409-310
E-mail: Standards sales: prodaja@iss.rs Education: iss-edukacija@iss.rs Information about standards: infocentar@iss.rs
Stevana Brakusa 2, 11030 Beograd
Main menu

dnaSRPS EN ISO 10993-3:2024

Biological evaluation of medical devices - Part 3: Evaluation of genotoxicity, carcinogenicity, reproductive toxicity, and developmental toxicity (ISO/FDIS 10993-3:2026)

General information

50.60     Jun 11, 2026

ISS

Z076

European Norm

11.100.20  

English  

Scope

This document specifies strategies for risk estimation and evaluation of biological harms with respect to:

genotoxicity;
carcinogenicity;
reproductive toxicity; and
developmental toxicity.

This document is applicable when the need to evaluate a medical device for potential genotoxicity, carcinogenicity, reproductive toxicity and developmental toxicity has been established.
This document is not applicable to active pharmaceutical ingredients of device-drug combination products or biological components of device-biologic combination products which are covered by regulations.
NOTE            Guidance on selecting relevant biological effects for medical devices is covered in ISO 10993-1.

Related directives

NOTE: If the word "harmonized" (marked in green) is not found in the field with the name of the directive, it means that the European standard is not cited in the OJEU.

2017/745

Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC

Life cycle

PREVIOUSLY

PUBLISHED
SRPS EN ISO 10993-3:2017

NOW

PROJECT
dnaSRPS EN ISO 10993-3:2024
50.60 Close of voting. Proof returned by secretariat
Jun 11, 2026

Related project

Adopted from FprEN ISO 10993-3 IDENTICAL

Adopted from ISO 10993-3:2026 IDENTICAL